A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.

This Phase 3 clinical trial is comparing a new acid-suppressing drug, Anaprazole 60 mg, against the established medication Rabeprazole 20 mg for treating reflux esophagitis — inflammation of the esophagus caused by acid reflux, confirmed by endoscopy. The goal is to determine whether Anaprazole heals the esophagus as effectively and safely as Rabeprazole over up to 8 weeks. Adults aged 18 to 75 who have been diagnosed with grade B, C, or D reflux esophagitis by endoscopy within the past 14 days may be eligible, unless they have serious heart, liver, or kidney disease, active ulcers, or other conditions affecting the esophagus. Participation involves taking the assigned medication daily for up to 8 weeks and attending clinic visits for monitoring. This summary was prepared to help patients understand the study in plain language.